Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques

• US 6,984,498 B2
• Filed: 04/30/2004
• Issued: 01/10/2006
• Est. Priority Date: 12/27/1999
• Status: Expired due to Fees

• Current Assignee: Edwin L. Adair
• Original Assignee: Edwin L. Adair
• Inventors: Adair, Edwin L.
• Primary Examiner(s): Leary, Louise N.
• Application Number:
  US10/836,464
• Publication Number:
  US 20040202612A1
• Time in Patent Office: 620 Days
• Field of Search: 435/29, 435/4, 435/968
• US Class Current: 435/29
• CPC Class Codes: A61K 49/0021 the fluorescent group being a small organic molecule
• CPC Class Codes: A61K 49/0036 Porphyrins used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546
• CPC Class Codes: A61K 51/0485 Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: Y10S 435/968 High energy substrates, e.g. fluorescent, chemiluminescent, radioactive

Abstract

A cancer screening method is provided, wherein the method is characterized by administering a compound to a patient, the compound being a complex of a fluorescent marker and a radioactive marker, in a dose emitting between 5 Gy and 20 Gy radiation. Cells are then collected preferably through non-invasive or minimally invasive means. If fluorescence is observed in the exfoliated cells, tomographic scanning is conducted to further locate and/or confirm suspected malignant areas or metastatic areas. Further observation or treatment may be conducted either through fluorescence guided endoscopy, photo-dynamic therapy, and/or radiation treatment.

Claims

1. A method of cancer screening comprising the steps of:

administering a compound to a patient for uptake into target cells, the compound having a fluorescent marker portion, and a radioactive portion in target cells, wherein said fluorescent marker portion is selected from the group consisting of 5-ALA, protoporphyrin IX, TCPP, hematoporphyrin derivative, photofrin, uroporphyrin, coproporphyrin, TPPS, and TMPP, and said radioactive portion is a radioisotope of copper;

collecting the targeted cells from the patient;

stimulating the collected targeted cells with a frequency of light that will cause pre-malignant and malignant cells to fluoresce;

conducting tomographic scanning of the patient after the stimulating step if fluorescence is observed; and

conducting radiation therapy by site selective ionizing radiation treatment from said radioactive portion of said compound wherein the compound is administered in a dose emitting between about 5 Gy and 25 Gy radiation.

2. A method, as claimed in claim 1, further including the step of:

conducting fluorescence guided endoscopy for further observation or treatment of areas found during the first conducting step.

3. The method of claim 1, wherein the compound is administered in a dose emitting between about 9 Gy and about 18 Gy radiation.

4. The method of claim 1, wherein the collected targeted cells are disaggregated prior to the stimulating step.